- Drug Pipelines
- December 2022
- 30 Pages
Global
From €2958EUR$3,250USD£2,536GBP
- Clinical Trials
- January 2024
- 60 Pages
Global
From €1138EUR$1,250USD£975GBP
- Clinical Trials
- January 2024
- 60 Pages
Global
From €1138EUR$1,250USD£975GBP
- Report
- October 2024
- 79 Pages
Global
From €3500EUR$4,120USD£3,106GBP
- Report
- October 2022
- 113 Pages
Global
From €3185EUR$3,500USD£2,731GBP
- Report
- May 2022
- 39 Pages
Global
From €2275EUR$2,500USD£1,951GBP
- Report
- May 2022
- 71 Pages
Global
From €2275EUR$2,500USD£1,951GBP
- Report
- May 2022
- 44 Pages
Global
From €2275EUR$2,500USD£1,951GBP
- Book
- April 2022
- 480 Pages
- Book
- September 2019
- 272 Pages
The Guanylate Cyclase market is a subset of the Drug Discovery market, which focuses on the development of new drugs and treatments for various diseases. Guanylate Cyclase is an enzyme that plays a role in the regulation of blood pressure, and is a target for drug discovery. Companies in this market are researching and developing new drugs that target this enzyme, in order to treat diseases such as hypertension, pulmonary arterial hypertension, and heart failure.
The Guanylate Cyclase market is highly competitive, with many companies investing in research and development to create new drugs and treatments. Companies in this market are also investing in clinical trials to test the efficacy of their drugs.
Some companies in the Guanylate Cyclase market include Novartis, Pfizer, Merck, AstraZeneca, and GlaxoSmithKline. Show Less Read more
